On April 3, 2023 BostonGene reported that it will participate and present at the hubXchange’s East Coast Genomics in Precision Oncology 2023, taking place April 5 in Boston, Massachusetts (Press release, BostonGene, APR 3, 2023, View Source [SID1234629783]). The event brings together executives from pharma and biotech to address and find solutions to the key issues that currently need to be addressed in genomics-led oncology precision medicine strategies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Elucidation of the Cellular and Molecular Features of the TME Underlying Immune Escape and IO Failure
Wednesday, April 5 | 1:20 PM ET
Speaker: Alexander Bagaev, PhD, VP, Product Development, BostonGene
This session will highlight BostonGene’s comprehensive profile of a patient’s disease for therapy selection and stratification for IO clinical trials to improve outcomes by using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with deep immunoprofiling and best-in-class analytics.
"I am excited to participate in the East Coast Genomics in Precision Oncology 2023 and to present how BostonGene’s transcriptional profiling and advanced analytics can reveal detailed characteristics of functional immune programs in the tumor microenvironment," said Alexander Bagaev, PhD, VP, Product Development at BostonGene. "Our comprehensive molecular profiling approach and innovative bioinformatics platform stratifies patients based on IO response and identifies the most effective therapy, ultimately improving patient outcomes."